Checkpoint Inhibitors

It was not long after the discovery of immune checkpoint molecules that it was shown that cancer cells evolve to express more inhibitory immune checkpoint molecules to help them evade the immune system.

However, immune checkpoints also give oncologists an opportunity to treat cancer in the same way: by either blocking the inhibitory molecules or by promoting the stimulation of the immune response. There are a growing number of drugs in the clinic and in clinical trials that operate in this way.

ichorbio supplies a number of biosimilars of therapeutic drugs that function as checkpoint inhibitors.

Checkpoint Inhibitors from ichorbio

4-1BB

$718.00$4,161.00

CD27

CD40

CD70

CTLA-4

LAG3

$718.00$4,161.00

PD-1

PD-L1

TIGIT

$718.00$4,161.00

TIM-3

$718.00$4,161.00

VISTA

$718.00$4,161.00